Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 ...

In the coming weeks, Quantum Biopharma will seek FDA permission for a clinical trial testing Lucid-MS, its therapy to slow myelin loss in MS.

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

The ACP received funding to help interpret research and support decisions about MS treatments for older adults with MS.

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma ” or the “Company ”), a biopharmaceutical ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Scientists hunting for treatments and cures for multiple sclerosis may have found an unlikely ally — the yak. The high-altitude, cold-hardy relative of the cow could be the key to a medical ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...